The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura.
about
Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research.Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.Understanding organ dysfunction in thrombotic thrombocytopenic purpura.A novel homozygous frameshift mutation in Exon 7 of the ADAMTS13 gene in a patient with congenital thrombotic thrombocytopenic purpura from India: a case report.
P2860
Q33377517-B3A3FE1D-4B50-4143-B83F-3B23B2E9AACDQ33401403-CBB33365-78EB-4150-A910-B1C42C3855C1Q33401647-70BA32E5-0BE6-4314-99A9-A00AA6583663Q33402274-CF5CDD8C-D3C6-4814-9BD9-B21558BB1236Q33408786-6DA89799-30F8-4D66-87B3-5CD14EF61102Q33411009-06BB60F2-4AB4-4F34-AD00-E78455E25CB3Q33416588-0144875E-46B7-479E-A5CC-E0C6C7801B60Q33418645-59177566-191A-44F6-9AC3-ACDFFB6584FCQ33419860-09C90B7A-C113-4209-ABC6-25F6AA56B35BQ47916648-7536FF54-7693-4B91-A99E-0D556F725DA7
P2860
The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The use of intermediate purity ...... otic thrombocytopenic purpura.
@ast
The use of intermediate purity ...... otic thrombocytopenic purpura.
@en
type
label
The use of intermediate purity ...... otic thrombocytopenic purpura.
@ast
The use of intermediate purity ...... otic thrombocytopenic purpura.
@en
prefLabel
The use of intermediate purity ...... otic thrombocytopenic purpura.
@ast
The use of intermediate purity ...... otic thrombocytopenic purpura.
@en
P2093
P2860
P1476
The use of intermediate purity ...... otic thrombocytopenic purpura.
@en
P2093
Kate Khair
Marie Scully
Michael Gattens
Ri Liesner
P2860
P304
P356
10.1111/J.1365-2141.2006.06264.X
P407
P577
2006-08-22T00:00:00Z